IgG Anticardiolipin Antibody Titer &gt;40 GPL and the Risk of Subsequent Thrombo-occlusive Events and Death

Levine, Steven R.; Salowich-Palm, Leeza; Sawaya, Kara L.; Perry, Mary Ellen; Spencer, Horace J.; Winkler, Harald; Alam, Zarina; Carey, John

doi:10.1161/01.str.28.9.1660

Cited by 211 publications

(110 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…696 A limited number of studies have examined the effect of antiphospholipid antibodies specifically on the risk for recurrent thromboembolic events after an initial TIA or stroke. [697][698][699] In the only study to exclusively enroll young adults <50 years of age, antiphospholipid antibodies were associated with increased risk for recurrent stroke or venous thromboembolism. 700 Other studies that enrolled older patients or a mixture of young and old patients with ischemic stroke indicated wide variability in the prevalence of antiphospholipid antibodies, from 6% to 46%, and inconsistent findings for an association.…”

Section: Antiphospholipid Antibodiesmentioning

confidence: 99%

“…700 Other studies that enrolled older patients or a mixture of young and old patients with ischemic stroke indicated wide variability in the prevalence of antiphospholipid antibodies, from 6% to 46%, and inconsistent findings for an association. [690][691][692][693][694][696][697][698][699]701 The wide variability reflects differences in diagnostic criteria, including persistence.…”

Section: Antiphospholipid Antibodiesmentioning

confidence: 99%

See 1 more Smart Citation

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

Kernan¹,

Ovbiagele²,

Black³

et al. 2014

Stroke

3,942

1,326

View full text Add to dashboard Cite

The aim of this updated guideline is to provide comprehensive and timely evidence-based recommendations on the prevention of future stroke among survivors of ischemic stroke or transient ischemic attack. The guideline is addressed to all clinicians who manage secondary prevention for these patients. Evidence-based recommendations are provided for control of risk factors, intervention for vascular obstruction, antithrombotic therapy for cardioembolism, and antiplatelet therapy for noncardioembolic stroke. Recommendations are also provided for the prevention of recurrent stroke in a variety of specific circumstances, including aortic arch atherosclerosis, arterial dissection, patent foramen ovale, hyperhomocysteinemia, hypercoagulable states, antiphospholipid antibody syndrome, sickle cell disease, cerebral venous sinus thrombosis, and pregnancy. Special sections address use of antithrombotic and anticoagulation therapy after an intracranial hemorrhage and implementation of guidelines.

show abstract

Section: Antiphospholipid Antibodiesmentioning

confidence: 99%

Section: Antiphospholipid Antibodiesmentioning

confidence: 99%

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

Kernan¹,

Ovbiagele²,

Black³

et al. 2014

Stroke

3,942

1,326

View full text Add to dashboard Cite

show abstract

“…Early studies showed an increased recurrent stroke risk associated with aPLs, 24,25 but later studies that included larger numbers of patients failed to find such an association. 8,26 The Antiphospholipid Antibodies and Stroke Study (n=1770), a prospective cohort study, reported that immunoreactivity to either aCL or lupus anticoagulant antibodies at the time of a first ischemic stroke did not influence the risk of subsequent thrombo-occlusive events over the following 2 years.…”

Section: November 2016mentioning

confidence: 99%

Antiphosphatidylserine Antibodies and Clinical Outcomes in Patients With Acute Ischemic Stroke

Peng

Zhong

et al. 2016

Stroke

View full text Add to dashboard Cite

Background and Purpose-Antiphosphatidylserine antibodies (aPS) have been associated with the risk of ischemic stroke.However, it remains unclear whether aPS will influence clinical outcomes in patients with acute ischemic stroke. Methods-A total of 3013 patients with acute ischemic stroke recruited from 26 hospitals across China from August 2009 to May 2013 were included in the study The primary outcome was a combination of death and major disability (modified Rankin Scale score ≥3) at 3 months after stroke. Secondary outcomes included death, major disability, recurrent stroke, and vascular events. Results-Composite outcome of death and major disability rates were 29.1% versus 23.9% in aPS-positive and aPS-negative groups. Compared with aPS-negative, adjusted odds ratios or hazard ratios (95% confidence interval) associated with aPS-positive were 1.35 (1.07-1.71), 1.63 (0.99-2.69), and 1.25 (0.98-1.59) for composite outcome of death or major disability, death, and major disability, respectively. For 1 interquartile range increase of aPS, the adjusted odds ratios or hazard ratios were 1.10 (1.01-1.20), 1.19 (1.05-1.35), and 1.05 (0.96-1.14), respectively. Adding aPS status to a model containing conventional risk factors improved risk prediction for composite outcome of death or major disability (net reclassification improvement index=11.3%, P=0.006; integrated discrimination improvement=0.2%, P=0.04). There was no significant association between aPS and risks of recurrent stroke and vascular events. Conclusions-We found that positive aPS increased risks of death or major disability at 3 months after an acute ischemic stroke, suggesting that aPS might be a prognostic marker for ischemic stroke.

show abstract

“…Patients were prospectively followed to estimate the effect of aCL titer on time to and risk of subsequent thrombo-occlusive events (stroke, transient ischemic attack, deep venous thrombosis, pulmonary embolism, myocardial infarction) and death. Patents with aCL titers > 40 GPL were younger, had more prior strokes, more frequent subsequent thrombo-occlusive events and death, and a shorter median time to event (Levine et al, 1997). The more recent study performed in 432 Taiwanese adults with cerebral ischemia disclosed an interesting impact of aCL IgG.…”

Section: Relationship Between Antiphospholipid Antibodies and Atherosmentioning

confidence: 97%

Antiphospholipid Antibodies and Their Association with Atherosclerotic Changes in Patients with Systemic Lupus Erythematosus – Review of Literature and Own Experiences

Fischer¹,

Flicinnski²,

Brzosko³

2012

Antiphospholipid Syndrome

View full text Add to dashboard Cite

IgG Anticardiolipin Antibody Titer >40 GPL and the Risk of Subsequent Thrombo-occlusive Events and Death

Abstract: Our data suggest that subsequent thrombo-occlusive events and death after focal cerebral ischemia associated with IgG aCL may occur sooner and more frequently with GPL > 40.

Cited by 211 publications

References 29 publications

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

Antiphosphatidylserine Antibodies and Clinical Outcomes in Patients With Acute Ischemic Stroke

Antiphospholipid Antibodies and Their Association with Atherosclerotic Changes in Patients with Systemic Lupus Erythematosus – Review of Literature and Own Experiences

Contact Info

Product

Resources

About